Çağatay ARSLAN, Ömercan TOPALOĞLU, Fatoş Dilan ATİLLA, Emel Ebru PALA

Cancer of Unknown Primary Presenting With a Giant Shoulder Mass in a Young Man: Prostate Adenocarcinoma

Cancer of unknown primary (CUP) is a metastatic tumor for which a standardized diagnostic workupfails to identify the site of origin at the time of making the diagnosis. The most frequent primary originsite is the lung and pancreas (40%), and the second most frequent primary origin site is the gastrointestinal system. For male patients with CUP, serum prostate specific antigen (PSA) level and free PSA/totalPSA ratio should be determined; if necessary, immunohistochemical staining for PSA and P504S shouldbe performed from the metastatic mass. Young patients with CUP should be attentively evaluated to establish the diagnosis and start treatment. We report the case of a young man who presented with a giantshoulder mass of unknown primary site and was diagnosed as having prostate adenocarcinoma.

PDF

___

1. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet 2012;379(9824):1428–35.
2. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39(14):1990– 2005.
3. Hemminki K, Bevier M, Hemminki A, Sundquist J. Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol 2012;23(7):1854–63.
4. Hainsworth JD, Greco FA. Management of patients with cancer of unknown primary site. Oncology (Williston Park) 2000;14(4):563–74.
5. Cho JY, Shim EJ, Kim IS, Nam EM, Choi MY, Lee KE, et al. Cancer of unknown primary finally revealed to be a metastatic prostate cancer: a case report. Cancer Res Treat 2009;41(1):45–9.
6. Sheridan T, Herawi M, Epstein JI, Illei PB. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol 2007;31(9):1351–5.
7. National Comprehensive Cancer Netwoek. NCCN Clinical Practice Guidelines in Oncology. Occult Primary (Cancer of Unknown Primary [CUP]). Version 1.2013. Available at: https://www2.tri-kobe.org/nccn/ guideline/archive/occult2013/english/occult.pdf. Accessed Sep 20, 2018.
8. Blaszyk H, Hartmann A, Bjornsson J. Cancer of unknown primary: clinicopathologic correlations. APMIS 2003;111(12):1089–94.
9. Bastide C, Bruyère F, Karsenty G, Guy L, Rozet F. Hormonal treatment in prostate cancer. [Article in French]. Prog Urol 2013;23(15):1246–57.